• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Phase 3 CEPHEUS Trial: DARA Plus VRd Is a Standard of Care for Frontline Treatment in Transplant-Ineligible Multiple Myeloma

by | Dec 10, 2024 | Myeloma News

Source: Pharmacy Times articles The phase 3 CEPHEUS trial demonstrated that adding daratumumab (DARA) to the VRd regimen significantly improves minimal residual disease negativity, progression-free survival, and overall response in transplant-ineligible or transplant...

ASH 2024: Circulating Tumor Cells Can Serve as Biomarker for Poor Outcomes in Multiple Myeloma

by | Dec 10, 2024 | Myeloma News

Source: Pharmacy Times articles Luca Bertamini, MD highlights the potential clinical implications of using circulating tumor cells as a biomarker in patients with newly-diagnosed multiple myeloma. Read More

ASH 2024: Expert Highlights Bolstered MRD Negativity, Survival With D-VRd in Newly-Diagnosed Multiple Myeloma

by | Dec 10, 2024 | Myeloma News

Source: Pharmacy Times articles Sonja Zweegman, MD, PhD, explains the improvements in minimum residual disease negativity found after treatment with daratumumab and the VRd regimen in patients with newly-diagnosed multiple myeloma who are transplant-ineligible. Read...

ASH 2024: New Treatments in Trial Pipeline Show Promising Survival Rates in R/R Multiple Myeloma

by | Dec 9, 2024 | Myeloma News

Source: Pharmacy Times articles Robert Rifkin, MD, FACP, discusses multiple abstracts featuring drugs demonstrating efficacy in patients with relapsed/refractory multiple myeloma. Read More

ASH 2024: Rapid Uptake of Bispecific Antibodies for R/R Multiple Myeloma Observed in Community Oncology Settings

by | Dec 9, 2024 | Myeloma News

Source: Pharmacy Times articles Ira Zackon, MD explains his analysis of bispecific antibody utilizaton for relapsed or refractory multiple myeloma in community oncology centers. Read More

Daratumumab Demonstrates Significant Benefit in High-Risk Smoldering Myeloma: Results from the Phase 3 AQUILA Study

by | Dec 8, 2024 | Myeloma News

Source: Pharmacy Times articles The AQUILA study demonstrates that early treatment with daratumumab significantly delays progression to symptomatic multiple myeloma, improves survival outcomes, and offers a well-tolerated alternative to traditional observation. Read...
« Older Entries
Next Entries »

Recent Content

  • Darzalex Regimen May Improve MRD Responses in Multiple Myeloma
  • Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
  • Hexamethylene amiloride induces lysosome-mediated cell death in multiple myeloma through transcription factor E3
  • Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study
  • Black Patients With Myeloma Face Taste, Skin Side Effects from Talvey
  • ASH 2024: Expert Discusses Challenges, Future Research Opportunities With Bispecific Antibodies in Multiple Myeloma
  • Blenrep Combo Improves Survival in Relapsed/Refractory Multiple Myeloma
  • Pseudokinase TRIB3 stabilizes SSRP1 via USP10-mediated deubiquitination to promote multiple myeloma progression
  • Phase 3 GMMG-HD7 Trial: Assessing the Impact of Isatuximab on MRD Negativity and PFS in Multiple Myeloma
  • Phase 3 CEPHEUS Trial: DARA Plus VRd Is a Standard of Care for Frontline Treatment in Transplant-Ineligible Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT